PL2884979T3 - Terapie skojarzone czerniaka obejmujące podawanie kobimetynibu i wemurafinibu - Google Patents

Terapie skojarzone czerniaka obejmujące podawanie kobimetynibu i wemurafinibu

Info

Publication number
PL2884979T3
PL2884979T3 PL13753131T PL13753131T PL2884979T3 PL 2884979 T3 PL2884979 T3 PL 2884979T3 PL 13753131 T PL13753131 T PL 13753131T PL 13753131 T PL13753131 T PL 13753131T PL 2884979 T3 PL2884979 T3 PL 2884979T3
Authority
PL
Poland
Prior art keywords
vemurafinib
melanoma
combination therapies
cobimetinib
administering
Prior art date
Application number
PL13753131T
Other languages
English (en)
Inventor
Gordon Bray
Iris T Chan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49035547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2884979(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL2884979T3 publication Critical patent/PL2884979T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0241—Advertisements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Business, Economics & Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Development Economics (AREA)
  • Accounting & Taxation (AREA)
  • Finance (AREA)
  • Strategic Management (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Theoretical Computer Science (AREA)
  • Marketing (AREA)
  • General Physics & Mathematics (AREA)
  • General Business, Economics & Management (AREA)
  • Economics (AREA)
  • Game Theory and Decision Science (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
PL13753131T 2012-08-17 2013-08-15 Terapie skojarzone czerniaka obejmujące podawanie kobimetynibu i wemurafinibu PL2884979T3 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261684673P 2012-08-17 2012-08-17
US201261705575P 2012-09-25 2012-09-25
US201261706026P 2012-09-26 2012-09-26
US201261722725P 2012-11-05 2012-11-05
US201361780708P 2013-03-13 2013-03-13
EP13753131.5A EP2884979B1 (en) 2012-08-17 2013-08-15 Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
PCT/EP2013/067050 WO2014027056A1 (en) 2012-08-17 2013-08-15 Combination therapies for melanoma comprising administering cobimetinib and vemurafinib

Publications (1)

Publication Number Publication Date
PL2884979T3 true PL2884979T3 (pl) 2019-11-29

Family

ID=49035547

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13753131T PL2884979T3 (pl) 2012-08-17 2013-08-15 Terapie skojarzone czerniaka obejmujące podawanie kobimetynibu i wemurafinibu

Country Status (31)

Country Link
US (3) US11087354B2 (pl)
EP (1) EP2884979B1 (pl)
JP (2) JP6335169B2 (pl)
KR (6) KR20240146112A (pl)
CN (2) CN104640545A (pl)
AU (1) AU2013304021B2 (pl)
BR (1) BR112015003418A2 (pl)
CA (2) CA2928396A1 (pl)
CL (1) CL2015000345A1 (pl)
CO (1) CO7180225A2 (pl)
DK (1) DK2884979T3 (pl)
EA (1) EA033573B1 (pl)
ES (1) ES2743427T3 (pl)
HK (1) HK1206605A1 (pl)
HR (1) HRP20191533T1 (pl)
HU (1) HUE044789T2 (pl)
IL (1) IL237065B (pl)
LT (1) LT2884979T (pl)
MX (1) MX367970B (pl)
MY (1) MY180613A (pl)
NZ (1) NZ744862A (pl)
PE (1) PE20151156A1 (pl)
PH (1) PH12015500186A1 (pl)
PL (1) PL2884979T3 (pl)
PT (1) PT2884979T (pl)
RS (1) RS59113B1 (pl)
SG (3) SG10201708494QA (pl)
SI (1) SI2884979T1 (pl)
UA (1) UA114923C2 (pl)
WO (1) WO2014027056A1 (pl)
ZA (1) ZA201500348B (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE044352T2 (hu) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
DK2884979T3 (da) 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015095842A2 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
WO2015191986A1 (en) * 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
CZ2015250A3 (cs) * 2015-04-14 2016-10-26 Zentiva, K.S. Amorfní formy vemurafenibu
BR112017025045A2 (pt) * 2015-05-22 2018-08-07 Plexxikon Inc plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600
TWI804919B (zh) * 2015-06-30 2023-06-11 美商建南德克公司 含藥物之立即釋放錠劑及形成該錠劑的方法
BR112018008882A8 (pt) 2015-11-03 2019-02-26 Univ Texas método para tratar um distúrbio proliferativo e produto farmacêutico
WO2017087851A1 (en) * 2015-11-19 2017-05-26 Genentech, Inc. Methods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors
WO2017095826A1 (en) * 2015-11-30 2017-06-08 The Regents Of The University Of California Combination therapy for treatment of melanoma
CN109689102A (zh) 2016-08-12 2019-04-26 基因泰克公司 Mek抑制剂,pd-1轴抑制剂,和vegf抑制剂的组合疗法
WO2018064299A1 (en) 2016-09-29 2018-04-05 Genentech, Inc. Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
WO2019139970A1 (en) * 2018-01-09 2019-07-18 Duke University Topical administration of mek inhibiting agents for the treatment of skin disorders
CN109879855B (zh) * 2019-03-26 2021-01-05 中国医学科学院医药生物技术研究所 靶向肿瘤细胞表面pd-l1分子的抑制剂及其应用
WO2021229439A1 (en) * 2020-05-12 2021-11-18 Novartis Ag Therapeutic combinations comprising a craf inhibitor
CN117940130A (zh) 2021-03-09 2024-04-26 基因泰克公司 用于脑癌治疗的贝伐拉非尼
CN117561062A (zh) 2021-04-06 2024-02-13 基因泰克公司 使用贝伐拉非尼和考比替尼或使用贝伐拉非尼、考比替尼和阿特珠单抗的组合疗法
WO2023220067A1 (en) * 2022-05-09 2023-11-16 Yale University Immunotherapy of skin cancer using mpla-loaded hpg nanoparticles
WO2025008650A1 (en) * 2023-07-03 2025-01-09 Országos Onkológiai Intézet Cse inhibitor for use in the treatment of a tumor in combination with a mapk inhibitor

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002365899B2 (en) 2001-12-04 2007-09-13 Onyx Pharmaceuticals, Inc. RAF-MEK-ERK pathway inhibitors to treat cancer
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
WO2005047542A1 (en) 2003-10-16 2005-05-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatments for inhibiting development and progression of nevi and melanoma having braf mutations
KR101190912B1 (ko) 2003-11-19 2012-10-12 어레이 바이오파마 인크. Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
JP5138938B2 (ja) 2003-12-19 2013-02-06 プレキシコン インコーポレーテッド Ｒｅｔ調節剤の開発のための化合物および方法
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
SI1913157T2 (sl) 2005-06-28 2017-02-28 Genentech, Inc. EGFR in KRAS mutacije za napoved bolnikovega odziva na zdravljenje z EGFR inhibitorjem
US9095581B2 (en) 2005-07-21 2015-08-04 Ardea Biosciences, Inc. Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
WO2007013997A2 (en) 2005-07-22 2007-02-01 H. Lee Moffitt Cancer Center And Research Institute Inhibition of the raf/mek/p-erk pathway for treating cancer
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
PL2073810T3 (pl) * 2006-09-13 2012-01-31 Takeda Pharmaceuticals Co Zastosowanie 2-6-(3-amino-piperydyn-1-ylo)-3-metylo-2,4-diokso-3,4-dihydro-2H-pirymidyn-1-ylometylo-4-fluoro-benzonitrylu do leczenia cukrzycy, raka, zaburzeń autoimmunizacyjnych i zakażeń HIV
EP2074226A2 (en) 2006-09-19 2009-07-01 Novartis AG Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
PL2412828T3 (pl) 2007-03-13 2013-11-29 Amgen Inc Mutacje K-ras i B-raf i terapia przeciwciałami anty-EGFr
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
CA2694646C (en) 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
AR072657A1 (es) 2008-02-29 2010-09-15 Genentech Inc Compuestos inhibidores de raf y metodos para su uso
WO2009111278A2 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
CA2716947A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
US20110003859A1 (en) 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
CA2738573C (en) 2009-04-03 2013-02-19 F. Hoffmann-La Roche Ag Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof
CN102859355B (zh) 2009-08-24 2015-10-07 基因泰克公司 通过检测kras突变和rtk表达水平来测定细胞对b-raf抑制剂治疗的敏感性
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
EP2488184A4 (en) 2009-10-12 2013-04-24 Glaxosmithkline Llc COMBINATION
AU2010314287A1 (en) * 2009-10-12 2012-05-03 F. Hoffmann-La Roche Ag Combinations of a PI3K inhibitor and a MEK inhibitor
WO2011104694A2 (en) 2010-02-26 2011-09-01 GAMMAGENETICS Sàrl Detection of braf v600e mutation by allele specific real time quantitative pcr (as-qpcr) using locked nucleic acids primers and beacon probes
EP2545187B1 (en) 2010-03-09 2018-09-05 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
WO2012027716A1 (en) 2010-08-27 2012-03-01 Collabrx, Inc. Method to treat melanoma in braf inhibitor-resistant subjects
CN103370064A (zh) * 2010-09-03 2013-10-23 百时美施贵宝公司 使用水溶性抗氧化剂的药物制剂
WO2012061683A2 (en) 2010-11-05 2012-05-10 Glaxosmithkline Llc Methods for treating cancer
WO2012068562A2 (en) 2010-11-19 2012-05-24 The Regents Of The University Of California Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas
CN104689318A (zh) 2010-11-19 2015-06-10 葛兰素史密斯克莱知识产权（第2号）有限公司 使用braf抑制剂的治疗方法
US9295669B2 (en) * 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
US20130172375A1 (en) 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
DK2884979T3 (da) * 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance

Also Published As

Publication number Publication date
WO2014027056A1 (en) 2014-02-20
LT2884979T (lt) 2019-09-10
DK2884979T3 (da) 2019-09-02
EP2884979B1 (en) 2019-06-26
KR20190057421A (ko) 2019-05-28
RS59113B1 (sr) 2019-09-30
EA033573B1 (ru) 2019-11-06
US20220172244A1 (en) 2022-06-02
JP2017160214A (ja) 2017-09-14
EA201590262A1 (ru) 2015-06-30
EP2884979A1 (en) 2015-06-24
US20240046303A1 (en) 2024-02-08
KR20220165811A (ko) 2022-12-15
HUE044789T2 (hu) 2019-11-28
KR20210108502A (ko) 2021-09-02
HRP20191533T1 (hr) 2019-11-29
CN110251512A (zh) 2019-09-20
PH12015500186A1 (en) 2015-04-06
JP2015531763A (ja) 2015-11-05
KR20150038068A (ko) 2015-04-08
AU2013304021A1 (en) 2015-02-12
CA2879252A1 (en) 2014-02-20
AU2013304021B2 (en) 2016-09-15
US12354130B2 (en) 2025-07-08
ES2743427T3 (es) 2020-02-19
BR112015003418A2 (pt) 2017-07-04
CA2879252C (en) 2017-10-10
IL237065A0 (en) 2015-03-31
KR20240146112A (ko) 2024-10-07
UA114923C2 (uk) 2017-08-28
US11783366B2 (en) 2023-10-10
ZA201500348B (en) 2019-07-31
KR20170044759A (ko) 2017-04-25
CO7180225A2 (es) 2015-02-09
NZ744862A (en) 2019-06-28
PT2884979T (pt) 2019-09-04
MX2015002031A (es) 2015-06-05
CL2015000345A1 (es) 2015-05-22
HK1206605A1 (en) 2016-01-15
PE20151156A1 (es) 2015-08-19
MY180613A (en) 2020-12-03
JP6335169B2 (ja) 2018-05-30
US20140093568A1 (en) 2014-04-03
US11087354B2 (en) 2021-08-10
SG11201500582UA (en) 2015-04-29
IL237065B (en) 2020-07-30
SG10201913359TA (en) 2020-02-27
CN104640545A (zh) 2015-05-20
CA2928396A1 (en) 2014-02-20
SI2884979T1 (sl) 2019-10-30
SG10201708494QA (en) 2017-11-29
MX367970B (es) 2019-09-11

Similar Documents

Publication Publication Date Title
IL237065B (en) Combined therapy for melanoma that includes the administration of cobimetinib and morphine
IL235826A0 (en) Diazaspirocycloalkane and azaspirocycloalkane
EP2806918A4 (en) METHODS AND DEVICES FOR SELF-REINABLE SYRINGES
EP2828258A4 (en) NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE
EP2867209A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USES
IL251974A0 (en) Antifibrosis compounds and their uses
GB201216649D0 (en) Agents and methods
EP2840938A4 (en) THERAPEUTIC CUSHION
PT2914254T (pt) Terapias de combinação para tratar cancros quimiorresistentes
GB201217439D0 (en) Combination therapy
ZA201504405B (en) 6-chloro-3-(phenyl-d5)-inden-1-one and use thereof
ZA201405392B (en) Substituted phenylimidazopyrazoles and use thereof
IL238174A0 (en) Combined treatment with Valasertiv
GB201301571D0 (en) Product and use
GB201214493D0 (en) Therapies
GB201222541D0 (en) Kiddibidet and pottibidet
IL218974A0 (en) Conaction bitwen coutch and playels
GB201202021D0 (en) Co-sleeper and breastfeeder
GB201202945D0 (en) Novel cancer therapies and methods
HUE048382T2 (hu) 6-klór-3-(fenil-d5)-inden-1-on és alkalmazása
GB201418806D0 (en) Generating and partitioning polynomials
GB201211543D0 (en) Combination therapy
GB201214985D0 (en) Modified therapeutic agents
GB201213712D0 (en) Modified therapeutic agents
GB201102232D0 (en) Inventions and therapy